A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
NCT ID: NCT07215559
Last Updated: 2025-12-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
200 participants
INTERVENTIONAL
2025-10-16
2027-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Macupatide (Macupatide + Eloralintide Placebo)
Participants will be administered macupatide subcutaneously (SC) and eloralintide placebo SC
Macupatide
Administered SC
Eloralintide Placebo
Administered SC
Eloralintide (Elorlintide + Macupatide Placebo)
Participants will be administered eloralintide SC and macupatide placebo SC
Eloralintide
Administered SC
Macupatide Placebo
Administered SC
Macupatide + Eloralintide
Participants will be administered eloralintide SC and macupatide SC
Macupatide
Administered SC
Eloralintide
Administered SC
Placebo (Macupatide Placebo + Elorlintide Placebo)
Participants will be administered eloralintide placebo SC and macupatide placebo SC
Macupatide Placebo
Administered SC
Eloralintide Placebo
Administered SC
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Macupatide
Administered SC
Eloralintide
Administered SC
Macupatide Placebo
Administered SC
Eloralintide Placebo
Administered SC
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Have an HbA1c ≥7.5% to ≤10.5% at screening
* Have been treated with any of the following, alone or in combination, for at least 3 months prior to screening
* Diet and exercise
* Stable dose of metformin
* Sodium-glucose cotransporter-2 (SGLT2) inhibitor
* Have had a stable body weight (\<5% body weight gain and/or loss) for the 3 months prior to screening
* Have a BMI of 27 or greater at screening
Exclusion Criteria
* Have a prior or planned surgical treatment for obesity, except prior liposuction or abdominoplasty, if performed \>1 year prior to screening
* Have any of the following cardiovascular conditions within 3 months prior to screening:
* acute myocardial infarction
* cerebrovascular accident (stroke)
* unstable angina, or
* hospitalization due to congestive heart failure
* Have a history of an active or untreated malignancy or are in remission from a clinically significant malignancy for less than 5 years, exceptions include
* basal or squamous cell skin cancer
* in situ carcinomas of the cervix, or
* in situ prostate cancer
* Have been prescribed any of the following receptor agonists (RA) or their combination for any indication within the last 6 months:
* amylin RA
* dual amylin and calcitonin RA
* glucagon-like peptide-1 receptor (GLP-1) RA
* glucose-dependent insulinotropic peptide (GIP)/GLP-1 RA
* GLP-1/glucagon (GCG) RAs, or
* GIP/GLP-1/GCG RAs
* Have used excluded antihyperglycemic medications within 3 months prior to screening (including, but not limited to, sulfonylureas, dipeptidyl peptidase-4 inhibitors, alpha-glucosidase inhibitors, thiazolidinediones, and meglitinides
* Have used insulin for diabetic control within the prior year (short term use in certain situations allowed
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eli Lilly and Company
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
Role: STUDY_DIRECTOR
Eli Lilly and Company
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Prime Medical Group, LLC dba Gilbert Center for Family Medicine, LLC
Gilbert, Arizona, United States
Central Phoenix Medical Clinic
Phoenix, Arizona, United States
Pima Heart
Tucson, Arizona, United States
SKY Clinical Research Network Group-Brown
Atlanta, Georgia, United States
Teak Research Consults
Lawrenceville, Georgia, United States
AGILE Clinical Research Trials, LLC
Sandy Springs, Georgia, United States
Pivotal Research Solutions
Stonecrest, Georgia, United States
Rophe Adult and Pediatric Medicine/SKYCRNG
Union City, Georgia, United States
Vector Clinical Trials
Las Vegas, Nevada, United States
Premier Research
Trenton, New Jersey, United States
Mercy Family Clinic
Dallas, Texas, United States
Velocity Clinical Research, Dallas
Dallas, Texas, United States
PlanIt Research, PLLC
Houston, Texas, United States
Aavon Clinical Trials
Richmond, Texas, United States
Consano Clinical Research, LLC
Shavano Park, Texas, United States
Texas Valley Clinical Research
Weslaco, Texas, United States
Kalo Clinical Research
West Valley City, Utah, United States
Eastern Virginia Medical School (EVMS) Medical Group
Norfolk, Virginia, United States
Clinical Research Partners, LLC
Richmond, Virginia, United States
Northwest Clinical Research Center
Bellevue, Washington, United States
Rainier Clinical Research Center
Renton, Washington, United States
Universal Research Group
Tacoma, Washington, United States
Centro de Investigaciones Metabólicas (CINME)
Buenos Aires, , Argentina
CENUDIAB
Buenos Aires, , Argentina
CEDIC
CABA, , Argentina
Instituto de Investigaciones Clínicas Córdoba
Córdoba, , Argentina
Clínica Universitaria Reina Fabiola
Córdoba, , Argentina
Go Centro Medico San Nicolás
San Nicolás, , Argentina
Emeritus Research
Botany, , Australia
Core Research Group
Brisbane, , Australia
Emeritus Research
Camberwell, , Australia
Cornerstone Dermatology
Coorparoo, , Australia
Momentum Darlinghurst
Darlinghurst, Sydney, , Australia
CDH Research Institute Pty Ltd
Maroochydore, , Australia
Momentum Sunshine
Melbourne, , Australia
AIM Research
Merewether, , Australia
San Juan Bautista School of Medicine - Clinical Research Unit
Caguas, , Puerto Rico
Mgcendo Llc
San Juan, , Puerto Rico
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Role: CONTACT
Phone: 317-615-4559
Email: [email protected]
Physicians interested in becoming principal investigators please contact
Role: CONTACT
Email: [email protected]
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Related Links
Access external resources that provide additional context or updates about the study.
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
J2V-MC-GZLF
Identifier Type: OTHER
Identifier Source: secondary_id
27721
Identifier Type: -
Identifier Source: org_study_id